Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. Statins and cancer risk
Your Article Summary
See Latest ArticlesPhase III Study Showed Lucentis Improved Vision in Patients with Branch Retinal Vein Occlusion
Genentech, 07/06/09
Genentech, Inc. announced that the Phase III study BRAVO showed Lucentis improved vision, as measured by the primary endpoint of mean change from baseline in best-corrected visual acuity at six months, in patients with macular edema due to branch retinal vein occlusion. The safety profile of Lucentis was consistent with previous experience and no new adverse events related to Lucentis were observed in the study. Retinal vein occlusion is a common cause of vision loss that occurs when blood flow through a retinal vein becomes blocked, such as by a blood clot.
Today in Major Studies...keeping you current
Receive free subspecialty "5-minute updates" via email
Carboplatin-Pemetrexed Adjuvant Chemotherapy in Resected Non-small Cell Lung Cancer (NSCLC): A Phase II Study
Anticancer Research, 11/16/09
Pivotal Data Published in the Journal Cancer Demonstrate that TREANDA Induced Durable Responses in Relapsed Indolent Non-Hodgkins Lymphoma
Cephalon, 11/06/09
Mycophenolate mofetil: An update
Drugs of Today, 11/05/09
Sponsor
Article Search
Sponsor